BLU 451
Alternative Names: BLU-451; LNG-451Latest Information Update: 09 Jun 2023
At a glance
- Originator Lengo Therapeutics
- Developer Blueprint Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 03 Jun 2023 Safety and efficacy data from a phase I/II CONCERTO trial in Non-small cell lung cancer released by Blueprint Medicines
- 02 Jun 2023 Adverse event data from a phase I/II CONCERTO trial in Non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 02 May 2023 9387557 - KDM,Intro and Dev